Special Issue "Liquid Biopsies in Lung Cancer"
Deadline for manuscript submissions: 31 December 2019
Dr. Natália Martins
Faculty of Medicine, University of Porto – Portugal; Institute for Research and Inovation in Health (i3S), University of Porto - Portugal
Interests: evidence-based medicine; phytochemistry; phytopharmacology; drug discovery; natural products biochemistry; bioactive molecules; functional foods; nutraceuticals
Dr. Gabriela Fernandes
Tumor biopsies are considered the standard for anatomopathological and molecular diagnosis. Besides being obtained by invasive methods, they only represent a point in time and a point in space of all tumor biology and evolution. For several years, clinicians and researchers dedicated to cancer have pursued the idea of non-invasive diagnosis, through the study of peripheral blood and other bodily fluids. Indeed, tumors release parts of themselves into the circulation (e.g. free nucleic acids, tumor cells, exosomes, among others), and these elements can be extracted and analyzed. Considering that lung cancer is one of the leading causes of cancer mortality, it is of utmost interest to ensure constant progress in cancer biology comprehension. In fact, the substantial knowledge reached in lung cancer biology has led to several advances in targeted therapies and immunotherapy, while the recent achievements in sequencing technologies have made this ambition a reality. Therefore, the development of the non-invasive evaluation of tumor-releasing or tumor-associated elements, called liquid biopsy, may offer a unique opportunity to help with lung cancer screening, to detect minimal residual disease and early relapses, to detect specific mutations, to monitor the development of treatment response and resistance mechanisms, as well as to assess immunotherapy-related parameters. Currently, liquid biopsy is conceived as an inescapable reality, with special emphasis on lung cancer management. However, their inclusion in both diagnostic and therapeutic decision-making processes raises many questions. Thus, and in a broad sense, all of the questions and advances that intersect both the present and future of liquid biopsies in lung cancer management are welcome in this Special Issue. Original articles, comprehensive and critical reviews, case reports and even letters are of utmost interest, given the expansive interest of this area.
Prof. Dr. Natália Martins
Dr. Gabriela Fernandes
Dr. Vanessa Santos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Liquid biopsies
- Lung cancer
- Cell-free DNA
- Circulating tumor DNA
- Next-generation sequencing
- Resistance mechanisms
- Predictive and prognostic biomarkers
- Genetic mutations
- Targeted therapy
- Biological monitoring